To verify whether NF-κB and AKT pathways are involved in enhanced pancreatic cancer cell proliferation induced by calponin 2 knockdown, NF-κB and AKT specific inhibitors PDTC and LY294002 (Merck, 548000 and 440202) were used to treat calponin 2-knockdown MIA-PaCa2 cells and control cells. This evidence concerns the gene CNN2 and pancreatic neoplasm.